Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of A Phase 2 Study Of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU
7/1/2014 9:07:09 AM
NOVATO, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Help employers find you! Check out all the jobs and post your resume.
comments powered by